The recent approval of ICI + VEGF combination therapy, Avastin + Tecentriq (atezolizumab plus bevacizumab), by the Food and Drug Administration (FDA) in May 2020 led to its replacement of the SOC in first-line advanced HCC, shifting MKIs increasingly towards second-line options. This evidence concerns the gene VEGFA and hepatocellular carcinoma.